Supplementary Material for: Angiopoietin as A Novel Prognostic Marker in Kidney Disease

Renal injury is among the leading causes of morbidity and mortality, however, there are no reliable indicators for determining the likelihood of developing CKD, CKD progression or AKI events. Vascular growth factors called angiopoietins have a role in endothelial function, vascular remodeling, tissue stabilization and inflammation, and have been implicated as prognostic and predictive markers in AKI. Although the exact mechanism of the relationship between kidney injury and angiopoietins is unknown, this review demonstrates that AKI patients have higher angiopoietin-2 levels and that higher angiopoietin-1 to angiopoietin-2 ratio may potentially be linked with a reduced risk of the chronic kidney disease progression. This review therefore emphasizes the importance of angiopoietin-2 and proposes that it could be an important predictor of AKI in clinical settings. There is a need for further large scale randomized clinical trials in order to have a better understanding of the significance of angiopoietin-2 and for the determination of its potential clinical implications.

肾损伤是引发发病率与死亡率居高不下的主要诱因之一，但目前尚无可靠指标可用于评估个体罹患慢性肾脏病（Chronic Kidney Disease, CKD）、慢性肾脏病进展以及急性肾损伤（Acute Kidney Injury, AKI）事件的风险概率。被称为血管生成素（angiopoietins）的血管生长因子，参与内皮功能调控、血管重塑、组织稳定以及炎症反应过程，且已被证实可作为急性肾损伤的预后与预测标志物。尽管肾损伤与血管生成素之间关联的确切机制尚未明确，但本综述证实，急性肾损伤患者的血管生成素-2（Angiopoietin-2）水平更高，且较高的血管生成素-1（Angiopoietin-1）与血管生成素-2的比值，或与慢性肾脏病进展风险降低存在潜在关联。因此，本综述着重强调了血管生成素-2的重要性，并提出其或可成为临床场景中急性肾损伤的重要预测因子。未来仍需开展大规模随机对照临床试验，以进一步明确血管生成素-2的临床价值，并确定其潜在的临床应用场景。